Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Eligibility Criteria

• 1. Positive beta HCG in female of child-bearing potential defined as not postmenopausal for 24 months or no previous surgical sterilization or lactating females.
• 2. Presence of clinically significant Grade 3 or greater toxicity from the previous treatment, as determined by PI.
• 3. Presence of uncontrolled fungal, bacterial, viral, or other infection not responding to appropriate therapy.
• 4. Active hepatitis B or C.
• 5. HIV with detectable viral load
• 6. Presence of active neurological disorder(s).
• 7. Active autoimmune disease within 12 months of enrollment
• 8. Active cerebral or meningeal involvement by the malignancy
• 9. Active (defined as requiring therapy) acute or chronic GVHD
• 10. Any other malignancy known to be active, except for treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.
• 11. Presence of any other serious medical condition that may endanger the patient at investigator criteria
• 12. Major surgery \<4 weeks prior to first dose of study drug
• 13. Allogeneic SCT or DLI \<12 weeks prior to first dose of study drug
• 14. Concomitant use of other investigational agents.
• 15. Concomitant use of other anti-cancer agents.
• 16. Patients receiving systemic steroid therapy at time of enrollment (physiological substitutive doses are allowed), or have received ATG within 14 days or Campath within 28 days of enrollment.
• 17. Patients receiving immunosuppressive therapy